Indivior Share Discussion Threads

[dealy] 09/7/2024 12:39

The CEO is very details driven.He has numbers on the tip of his tongue. General message is one of lumpiness with regard to patient numbers (roll on / roll off effects) and unevenness of Medicaid insurance timing etc.On thr litigation settlement: feels this was a good deal.for shareholders (avoids trial risk), 5/7 insurance are covered by this settlement, the remaining 2 are early stage claims only at this point.On Perseris discontinuation: I didn't understand or remember what he said, other than commiting to help those affected

[casholaa] 09/7/2024 12:39

That's what I was thinking. It may have started already too!

[swinsco] 09/7/2024 12:36

I expect the yanks will want the days lows before a turn up.

[casholaa] 09/7/2024 12:29

Sharp or slim, I just can distinguish in the state I am in

[dealy] 09/7/2024 12:26

on the subject of buybacks, the CEO said, "Given the share price" they will "actively assess" the use of cash (which seems to imply they will allocate more cash to buy backs)

[swinsco] 09/7/2024 12:26

Would be interested in your general thoughts once it's over, Dealy. Thanks.

[dealy] 09/7/2024 12:14

CEO sounds razor sharp

[swinsco] 09/7/2024 12:12

Webinar must be going well then!

[gonuts1] 09/7/2024 11:13

It took plenty at sub 700, averaging 693p; it went down to 663, and MMS was hitting bid. It would be nice to sell at 850p.

Plenty from my CPX profit.

[sbb1x] 09/7/2024 11:11

Ask moving up now....

[grupo] 09/7/2024 10:55

Indivior cuts jobs and discontinues sales of schizophrenia medication

By This Is Money
DAILY MAIL

Updated: 11:38 BST, 9 July 2024


Indivior shares nosedived on Tuesday after the drugmaker slashed its profit guidance and revealed it would discontinue sales of a schizophrenia drug.

The group, which switched its primary listing to the US last month but continues to trade on the FTSE 250, told investors it would cut 130 jobs related to the discontinuation of sales of Perseris.

Mark Crossley, chief executive, said expectations of higher payer management related to Perseris made production 'no longer financially viable' and so it would be discontinued.


Indivior will continue to supply Perseris to avoid patient care disruption for the foreseeable future, but said it will no longer deploy a dedicated sales force.

Indivior shares were down 38.7 per cent to 723.5p in early trading in London on Tuesday, having lost around 50 per cent over the last year.

The firm also told shareholders that net revenue for its opioid disorder drug Sublocade continues to be weak, due primarily to the elimination of Covid-19 emergency measures related to automatic Medicaid coverage renewals in the US.




Crossley said: 'As we look to the second half of the year, the US government has extended renewal allowances for certain States which will further delay the annualisation of this significant headwind.

'We are therefore reducing our FY 2024 guidance to reflect these impacts.'

But Crossley added that Indivior remains 'firm in our conviction that Sublocade's unique profile to address high-powered synthetic opioids', such as fentanyl, provides the group with 'a tremendous opportunity to meet the growing and changing needs of patients'.

He said: 'As a result, we continue to be confident that Sublocade will achieve a net revenue run rate of $1billion as we exit 2025 and ultimately meet our target of greater than $1.5billion in peak annual net revenue, underpinning the successful delivery of our medium-term profitable growth ambitions.'

[casholaa] 09/7/2024 10:09

Emergent BioSolutions among others also make narcan

[7rademark] 09/7/2024 09:49

Furthermore the company would have certainly not expected this % fall given they have been buying their shares back at higher prices recently and just yesterday. I would imagine they are buying heavily as we speak.

[7rademark] 09/7/2024 09:46

These markets honestly. 40% down is overdone when you work out the reduction in mcap. Given the recent fall in share price I just can not see the justification for it. I would expect a considerable recovery today.

[baddeal] 09/7/2024 09:35

Yep I have shares in both as well. Quite a day

[dealy] 09/7/2024 09:31

Story of 2 of my holdings today: Capita and Indivior. Capita has an amazing event (disposal worth as much as the entire market cap) and it goes up only 20%Indivior down 43% on its news.The red is always redder than the blue is bluer

[tsmith2] 09/7/2024 08:55

would agree. it's a good company. bought in

[dealy] 09/7/2024 08:44

interesting. is there a relationship between narcan and indivior ?

[casholaa] 09/7/2024 08:34

This is worth having a look at...

[casholaa] 09/7/2024 08:31

I think the lesson here is not to dabble in drugs.

[dealy] 09/7/2024 08:22

the company claims that these are just temporary set backs

[ricky46] 09/7/2024 08:22

I wonder were the dust will settle though, you’d think the buybacks would be hammered now if it’s classed as cheap

[elsa7878] 09/7/2024 08:18

Main product sales below forecasts.
Secondary product which in the medium term was going to compensate for lower sales in the primary product now discontinued.
Costs associated with the above.
Litigation settled for an action they thought they would win.
Ongoing multiple litigations.
Potential litigation around Nasdaq listing (guaranteed I would think bearing in mind how close this statement is to the listing date).
What's there to like...?

[dealy] 09/7/2024 08:17

I have re-read the update. It looks like the management are realistic and proactive. This is an over reaction

[swinsco] 09/7/2024 08:16

The directors selling at 1700 was always a concern for me.. lost and out here. Gla